10
Views
0
CrossRef citations to date
0
Altmetric
Review

Emerging drugs in prostate cancer

&
Pages 303-316 | Published online: 24 Feb 2005

Bibliography

  • BORING CC, SQUIRES TS, TONG T: Cancer statistics 1993. CA Canced. Clin. (1993) 43:7–26.
  • AMERICAN CANCER SOCIETY: Cancer facts 8z figures - 1997. The Society, Atlanta (1997).
  • DIJKMAN GA, DEBRUYNE FMJ: Epidemiology of prostate cancer. Eur. Urol. (1996) 30:281–295.
  • BOCCON-GIBOD L: The management of localised cancer of the prostate. Eur. Urol. (1996) 29(Suppl. 2) :62–68.
  • CRAWFORD ED: Combined androgen blockade. Eur. Urol. (1996) 29\(Suppl. 2):54–61.
  • NEWLING DVVVV: The palliative therapy of advanced prostate cancer with particular reference to the results of recent European clinical trials. Br. J. Urol. (1997) 79 (Suppl. 1) :72–81.
  • ••Comprehensive review of the issues surrounding the treatment of advanced prostate cancer.
  • HELGASON AR, ADOLFSSON J, DICKMAN P, et al.: Waning sexual function - the most important disease-specific distress for patients with prostate cancer. Br. J. Cancer (1996) 73:1417–1421.
  • FERNANDEZ DEL MORAL P, DIJKMAN GA, DEBRUYNE FMJ, et al.: Three-month depot of goserelin acetate: clinical efficacy and endocrine profile. Urology (1996) 48:894–900.
  • NODA M, TSUSHIMA T, NASU Yet al.: The effect of a gonadotrophin-releasing hormonal agonist on bone mineral density of prostatic cancer patients. J. Urol. (1997) 157. Abstract 907.
  • NEWLING DWW: Anti-androgens in the treatment of prostate cancer. Br. J. Urol. (1996) 77:776–784.
  • MCLEOD DG: Tolerability of nonsteroidal antiandrogens in the treatment of advanced prostate cancer. Oncologist (1997) 2: 18–27.
  • ROBINSON MRG: A further analysis of European Organisation for Research and Treatment of Cancer protocol 30805: orchidectomy versus orchidectomy plus cyproterone acetate versus low-dose diethylstilboestrol. Cancer (1993) 72:3855–3857.
  • RAGHA VAN D, KOCZWARA B, JAVLE M: Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer. Eur. J. Cancer (1997) 33:566–574.
  • NEWLING DVVVV: The management of hormone refractory prostate cancer. Eur. Urol. (1996) 29 (Suppl. 2) :69–74.
  • KIRBY RS, CHRISTMAS TJ, BRAWER M: Management of hormone escaped prostate cancer. In: Prostate Cancer. Mosby (1996).
  • GALBRAITH SM, DUCHESNE GM: Androgens and prostate cancer: biology, pathology and hormonal therapy. Eur. J. Cancer (1997) 33:545–554.
  • SCHELLHAMMER P, SHARIFI R, BLOCK N, et al.: Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostate carcinoma: final report of a double-blind randomised, multicenter trial. Urology (1997) 50:330–336.
  • BLACKLEDGE GRP, COCKSHOTT I, FURR BJA: Casodex (bicalutamide): overview of a new antiandrogen developed for the treatment of prostate cancer. Eur. Urol. (1997) 31: 30–39.
  • TUNN UW, MELAMED RJ, SCHNAARS Y et al.: Tolerability and hormonal suppression of the LHRH -antagonist cetrorelix in patients with prostate cancer. J. Urol. (1997) 157(Suppl.) :141.
  • HARNING R, MAILLIARD JA, ROSPOND R, et al.: Deslorelin (a new LHRH agonist) significantly reduces tumor flare during early treatment of Stage D2 prostate cancer. Proceedings of the Annual Meeting of the American Association of Cancer Research (1993) 34:202, A1206.
  • FDC Reports: The Pink Sheet (29 November 1995).
  • SHAH J, MONROE S, WOLFE L, et al.: Pharmacokinetics and pharmacodynamics of a novel GnRH antagonist (RS-26306) in humans. Pharm. Res. (1991) 8 (Suppl.):249.
  • Clinical trials update. Scrip (1997) 10:2200.
  • TALWAR GP: Vaccines for control of fertility and hormone-dependent cancers. Immunol. Cell Biol. (1997) 75:184–189.
  • DORR FA, SIKIC BI, NEMUNAITIS J, et al.: ISIS 3521/CGP 64128A-antisense to protein kinase C-alpha. Eur. J. Cancer (1997) 33(Part A, Suppl.5) :52.
  • MCKEAGE MJ, RAYNAUD F, WARD J, et al.: Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J. Clin. Oncol. (1997) 15:2691–2700.
  • TYRRELL C, LIAZAL STUDY GROUPS: Liazal versus cyproterone acetate or prednisone in hormone-resistant prostate cancer: results of two clinical trials. Ann. Oncol. (1996) 7\(Suppl. 5):57.
  • Clinical trials update. Scrip (1996) 21:2152.
  • BOASBERG P, HARBAUGH B, ROTH B, et al.: Marimastat. A novel matrix metalloprotease inhibitor in patients with hormone refractory prostate cancer. Proc. Am. Soc. Clin. Oncol. (1996) 15:258.
  • Clinical trials update. Scrip (18 July 1997) 20:2250.
  • Phase I/II data with Sugen's SU101. Marketletter (26 May 1997) 24:21.
  • TRAXLER PM: Protein tyrosine kinase inhibitors in cancer treatment. Exp. Opin. Ther. Patents (1997) 7:571–588.
  • DAWSON NA, FIGG WD, COOPER MR, et al.: Phase II trial of suramin, leuprolide and flutamide in previously untreated metastatic prostate cancer. J. Clin. Oncol. (1997) 15:1470–1477.
  • YODEN T, OKADA M, KAWAMINAMI E, et al.: Synthesis and biological evaluation ofnovel non-steroidal inhibitors of steroid 17,20 lyase. 213th American Chemical Society National Meeting (1997). Abstract MEDI 206.
  • CARDUCCI MA, DEWEESE TL, NELSON WG, et al.: Prostate cancer treatment strategies based on tumor-specific biological principles: future directions. Semin. Oncol. (1996) 23(6 Suppl. 14):56–62.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.